NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Show more

Location: 9119 Gaither Road, Gaithersburg, MD, 20877, United States | Website: https://www.neximmune.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

139

52 Wk Range

$0.00 - $7.05

Previous Close

$0.00

Open

$0.00

Volume

N/A

Day Range

$0.00 - $0.00

Enterprise Value

-2.424M

Cash

2.424M

Avg Qtr Burn

-4.401M

Insider Ownership

16.72%

Institutional Own.

0.00%

Qtr Updated

06/30/24